Objectives {7}
malaria
MALARIA, EVENTS
Primary objective:To determine the safety (in humans) and efficacy of ivermectin MDA (to humans or human and livestock simultaneously) for the prevention of malaria.Note these co-primary objectives are determined in different populations. The efficacy endpoint is primarily measured in children under 5 years of age and safety is determined by anyone who receives the drug. Given the inclusion criteria, there might be a small overlap between the two populations.Secondary objectives:To assess the efficacy of the intervention using complementary methods (efficacy)To assess the safety of the intervention with complementary methods (safety)To assess the PK of the proposed ivermectin dose/regime in its relationship with efficacy and safety outcomes (efficacy and safety)To assess the impact of ivermectin MDA at the proposed regimen on the prevalence of selected ectoparasitic NTDs (efficacy on NTDs and acceptability)To assess the relationship between malaria incidence in children and community prevalence at the peak of the malaria season (this serves for prevalence outcomes and paves the way for future studies or future evaluation using this outcome which could require fewer resources).To assess the relationship between active and passive surveillance for malaria at health facility (this serves as validation of passive surveillance and paves the way for future studies using this outcome which is much less resource-consuming while ensuring no key safety events are missed)To assess the accuracy for malaria diagnosis of two different malaria rapid diagnostic tests (RDTs) used in comparison to PCR (this is directly linked to efficacy as determined by RDTs)